Maurizio Denaro Named General Manager of The Aptuit Center for Discovery & Development
Aptuit has announced that Maurizio Denaro has assumed responsibilities as general manager of The Aptuit Center for Discovery & Development in Verona, Italy.
Aptuit has announced that Maurizio Denaro has assumed responsibilities as general manager of The Aptuit Center for Discovery & Development in Verona, Italy.
Denaro's career has included corporate and R&D leadership roles at global life science companies in both Europe and the United States, including Bracco Imaging, where he was responsible for the ultrasound business unit, Marion Merrell Dow, OSI Pharmaceuticals, Amylin Pharmaceuticals, and Hoechst Marion Roussel.
After earning a degree in Medicine from the University of Bologna, Italy, Denaro continued his post-doctoral studies in the United States at Stanford Medical School's Department of Genetics and as a senior researcher at the Wallenburg Laboratory, Uppsala University, Sweden. He then became a research associate in Experimental Oncology at the Centro di Riferimento Oncologico in Aviano, Italy. Denaro is credited with the filing of 19 patents and his findings have appeared in 59 publications.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
